JP2020502154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502154A5 JP2020502154A5 JP2019532071A JP2019532071A JP2020502154A5 JP 2020502154 A5 JP2020502154 A5 JP 2020502154A5 JP 2019532071 A JP2019532071 A JP 2019532071A JP 2019532071 A JP2019532071 A JP 2019532071A JP 2020502154 A5 JP2020502154 A5 JP 2020502154A5
- Authority
- JP
- Japan
- Prior art keywords
- plasminogen
- pharmaceutical composition
- subject
- composition according
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013566 Plasminogen Human genes 0.000 claims 13
- 108010051456 Plasminogen Proteins 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 208000029078 coronary artery disease Diseases 0.000 claims 4
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims 3
- 208000026758 coronary atherosclerosis Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 201000006370 kidney failure Diseases 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002440 hepatic effect Effects 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000015163 Biliary Tract disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010007688 Carotid artery thrombosis Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008096 Cerebral atrophy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008132 Cerebral thrombosis Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 201000006368 chronic pyelonephritis Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 230000002550 fecal effect Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 208000018914 glucose metabolism disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 229940125697 hormonal agent Drugs 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 108010049112 miniplasminogen Proteins 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 206010033675 panniculitis Diseases 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000011251 protective drug Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016110168 | 2016-12-15 | ||
| CN2016110172 | 2016-12-15 | ||
| CNPCT/CN2016/110168 | 2016-12-15 | ||
| CNPCT/CN2016/110172 | 2016-12-15 | ||
| PCT/CN2017/089043 WO2018107684A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防动脉粥样硬化及其并发症的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502154A JP2020502154A (ja) | 2020-01-23 |
| JP2020502154A5 true JP2020502154A5 (enExample) | 2020-08-06 |
| JP7161217B2 JP7161217B2 (ja) | 2022-10-26 |
Family
ID=62557882
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532073A Active JP7160351B2 (ja) | 2016-12-15 | 2017-06-19 | 脂肪代謝障害およびその関連疾患を予防および治療するための方法 |
| JP2019532071A Active JP7161217B2 (ja) | 2016-12-15 | 2017-06-19 | アテローム性動脈硬化症およびその合併症を予防するための方法 |
| JP2019532070A Active JP7158740B2 (ja) | 2016-12-15 | 2017-06-19 | 冠状動脈アテローム性硬化症およびその合併症を治療するための方法 |
| JP2019531975A Active JP7214225B2 (ja) | 2016-12-15 | 2017-06-19 | 脂肪肝を予防および治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532073A Active JP7160351B2 (ja) | 2016-12-15 | 2017-06-19 | 脂肪代謝障害およびその関連疾患を予防および治療するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532070A Active JP7158740B2 (ja) | 2016-12-15 | 2017-06-19 | 冠状動脈アテローム性硬化症およびその合併症を治療するための方法 |
| JP2019531975A Active JP7214225B2 (ja) | 2016-12-15 | 2017-06-19 | 脂肪肝を予防および治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11478535B2 (enExample) |
| EP (4) | EP3556391A4 (enExample) |
| JP (4) | JP7160351B2 (enExample) |
| CN (4) | CN110366425A (enExample) |
| CA (4) | CA3047168A1 (enExample) |
| TW (9) | TWI746580B (enExample) |
| WO (8) | WO2018107685A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3391902T5 (da) | 2015-12-18 | 2024-09-23 | Talengen Int Ltd | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
| CN110114080A (zh) | 2016-12-15 | 2019-08-09 | 泰伦基国际有限公司 | 一种预防和治疗皮肤纤维化的方法 |
| CN110366425A (zh) * | 2016-12-15 | 2019-10-22 | 泰伦基国际有限公司 | 一种预防动脉粥样硬化及其并发症的方法 |
| JP7171572B2 (ja) | 2016-12-15 | 2022-11-15 | タレンゲン インターナショナル リミテッド | 糖尿病を治療するための新しい方法 |
| WO2018108161A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| EP3556385A4 (en) | 2016-12-15 | 2020-12-30 | Talengen International Limited | PROCESS FOR ALLEGING HEART DISEASE |
| TWI714862B (zh) * | 2017-06-19 | 2021-01-01 | 大陸商深圳瑞健生命科學硏究院有限公司 | 一種調控glp-1/glp-1r的方法和藥物 |
| CN115551534A (zh) * | 2020-02-26 | 2022-12-30 | 泰伦基国际有限公司 | 一种预防和治疗血压异常病症的方法和药物 |
| KR20220156935A (ko) * | 2020-03-24 | 2022-11-28 | 탈렌젠 인터내셔널 리미티드 | 헌팅톤병의 치료 방법 및 약물 |
| EP4140498A4 (en) * | 2020-05-11 | 2023-11-01 | Talengen International Limited | METHOD AND DRUGS FOR TREATING SPINAL MUSCLE ATROPHY |
| CN112056563A (zh) * | 2020-09-15 | 2020-12-11 | 王胜林 | 用于修复脂质代谢障碍的营养素组合物及其应用 |
| CN113041247A (zh) * | 2021-04-21 | 2021-06-29 | 中山大学孙逸仙纪念医院 | 伊玛替尼在防治新型冠状病毒及并发症药物中的应用 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4245051A (en) | 1978-03-30 | 1981-01-13 | Rockefeller University | Human serum plasminogen activator |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4658830A (en) | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
| DE3515869A1 (de) | 1985-05-03 | 1986-11-13 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung optisch aktiver azolderivate |
| JPS62153224A (ja) | 1985-12-27 | 1987-07-08 | Green Cross Corp:The | プラスミノゲン製剤 |
| GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| JP2764264B2 (ja) | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| AU4661493A (en) | 1992-07-01 | 1994-01-31 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| US5520912A (en) | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| DK125693D0 (enExample) | 1993-11-05 | 1993-11-05 | Novo Nordisk As | |
| DE4411143C2 (de) | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| JP2002510209A (ja) | 1997-06-26 | 2002-04-02 | カロリンスカ イノベイションズ アクチボラゲット | インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５ |
| US7317003B2 (en) | 1998-09-04 | 2008-01-08 | National University Of Singapore | Small peptides having anti-angiogenic and endothelial cell inhibition activity |
| US6465424B1 (en) * | 1999-02-17 | 2002-10-15 | Bristol-Myers Squibb Company | Anti-angiogenic agent and method for inhibiting angiogenesis |
| AU3605800A (en) * | 1999-02-24 | 2000-09-14 | Henry Ford Health System | An anti-angiogenic kringle protein and its mutants |
| US6899877B2 (en) | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
| US7544500B2 (en) | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
| US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US20020159992A1 (en) | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| US20030054988A1 (en) * | 2000-11-02 | 2003-03-20 | Weidong-Richard Ji | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
| WO2003014145A2 (en) | 2001-08-10 | 2003-02-20 | Novartis Ag | Peptides that bind to atherosclerotic lesions |
| US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| CN1408431A (zh) | 2001-09-21 | 2003-04-09 | 北京华兴生生物技术有限公司 | 治疗与新生血管生成相关疾病的基因工程药物 |
| US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| DE10390418D2 (de) * | 2002-02-06 | 2005-01-13 | N Zyme Biotec Gmbh | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen |
| EP1472346A2 (de) | 2002-02-06 | 2004-11-03 | N-Zyme BioTec GmbH | Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| JP2006507297A (ja) | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| PL374126A1 (en) | 2002-05-17 | 2005-10-03 | Esperion Therapeutics, Inc. | Methods and copositions for the treatment of ischemic reperfusion |
| CN101518533A (zh) | 2002-12-06 | 2009-09-02 | 法布罗根股份有限公司 | 脂肪调节 |
| CN1726191A (zh) | 2002-12-10 | 2006-01-25 | 惠氏公司 | 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代的吲哚氧代－乙酰氨基乙酸衍生物 |
| CN1451746A (zh) | 2003-03-20 | 2003-10-29 | 广州市启源生物科技有限公司 | 人纤溶酶原Kringle 5缺失突变重组多肽 |
| JPWO2005026127A1 (ja) | 2003-09-11 | 2006-11-16 | 株式会社医薬分子設計研究所 | プラスミノゲンアクチベータインヒビター−１阻害剤 |
| EP1689897B1 (en) | 2003-09-24 | 2007-05-09 | Alstom Technology Ltd | Braze alloy and the use of said braze alloy |
| JP4740531B2 (ja) | 2003-09-30 | 2011-08-03 | 雪印乳業株式会社 | 骨吸収抑制剤 |
| JP5026254B2 (ja) | 2004-04-22 | 2012-09-12 | グリフオルス・セラピユーテイクス・インコーポレーテツド | 組換え的に改変されたプラスミン |
| US8357147B2 (en) | 2005-08-17 | 2013-01-22 | Spinal Restoration, Inc. | Method for repairing intervertebral discs |
| FR2882654B1 (fr) * | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| WO2006095713A1 (ja) | 2005-03-08 | 2006-09-14 | Institute Of Medicinal Molecular Design. Inc. | プラスミノゲンアクチベータインヒビター－１阻害剤 |
| JP2008534508A (ja) | 2005-03-22 | 2008-08-28 | メドスター ヘルス インコーポレイテッド | 心血管疾患を診断および処置するための送達システムおよび方法 |
| US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| US20090123582A1 (en) | 2006-03-24 | 2009-05-14 | Akiko Kuwahara | Ameliorating Agent for Metabolic Syndrome |
| EP2056864B1 (en) | 2006-08-28 | 2013-12-11 | Omnio Healer AB | Candidates against infection |
| US20100028321A1 (en) | 2006-08-28 | 2010-02-04 | Omnio Healer Ab | Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| US20090093442A1 (en) | 2006-10-20 | 2009-04-09 | Lynch Stephanie K | Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
| CN101219219B (zh) | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
| CN101015686B (zh) | 2007-02-06 | 2010-05-19 | 中国人民解放军军事医学科学院基础医学研究所 | 一种溶栓药物增效剂及其制备方法 |
| US20080200387A1 (en) * | 2007-02-15 | 2008-08-21 | Hua-Lin Wu | Anti-angiogenic protein, composition and use thereof |
| AR067446A1 (es) | 2007-07-11 | 2009-10-14 | Otsuka Pharma Co Ltd | Un medicamento para tratar higado graso que comprende cilostazol |
| AT505574B1 (de) * | 2007-08-10 | 2009-09-15 | Affiris Forschungs & Entwicklungs Gmbh | Mimotope zur behandlung von atherosklerose |
| BRPI0816560A2 (pt) | 2007-10-23 | 2015-09-01 | Inst Med Molecular Design Inc | Método de inibição de produção de pai-1 método para prevenção ou melhora de uma doença causada por uma super-produção de pai-1" |
| US20090239868A1 (en) | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
| WO2009073471A1 (en) | 2007-11-29 | 2009-06-11 | Talecris Biotherapeutics, Inc. | Recombinantly modified plasmin |
| US8431363B2 (en) | 2008-01-09 | 2013-04-30 | Intrexon Corporation | Polynucleotides encoding therapeutic inhibitors of PAI-1 |
| US20090208448A1 (en) | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
| WO2010076655A1 (en) | 2008-12-30 | 2010-07-08 | Ikfe Gmbh | Biomarkers for adipose tissue activity |
| WO2010083570A1 (en) | 2009-01-23 | 2010-07-29 | The University Of Sydney | Novel metabolic disease therapy |
| EP2607348B8 (en) | 2009-03-31 | 2021-04-21 | Renascience Inc. | Plasminogen Activator Inhibitor-1 Inhibitor |
| EP2424561A2 (en) | 2009-04-30 | 2012-03-07 | Catherine Blondel | Methods for treating ocular conditions |
| EP2451835A1 (en) | 2009-07-10 | 2012-05-16 | ThromboGenics N.V. | Variants of plasminogen and plasmin |
| CN105031605A (zh) | 2009-08-12 | 2015-11-11 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
| CN101628113B (zh) | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
| CN101897925B (zh) * | 2009-12-16 | 2015-04-29 | 成都百康医药工业药理毒理研究院 | 一种治疗代谢综合症的药物组合物 |
| WO2011139974A2 (en) | 2010-05-03 | 2011-11-10 | Abbott Laboratories | Anti-pai-1 antibodies and methods of use thereof |
| WO2012021287A2 (en) * | 2010-08-09 | 2012-02-16 | The Johns Hopkins University | Methods for the treatment and prevention of metabolic disorders |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| ES2583082T3 (es) | 2011-01-05 | 2016-09-19 | Thrombogenics N.V. | Variantes de plasminógeno y plasmina |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| US9078904B2 (en) * | 2011-02-10 | 2015-07-14 | Trustees Of Dartmouth College | Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis |
| KR20140010126A (ko) | 2011-03-03 | 2014-01-23 | 터서스 파마수티칼 엘엘씨 | C16:1n7-팔미톨리에이트를 포함하는 조성물들 및 방법들 |
| CN102199587B (zh) | 2011-03-24 | 2013-06-19 | 广东药学院 | 人纤溶酶原功能性突变体及其制备方法和应用 |
| MX2013011294A (es) * | 2011-03-30 | 2014-10-06 | Univ Texas | Metodos y composiciones para dirigir celulas adiposas en mamiferos. |
| CN102188699A (zh) | 2011-05-06 | 2011-09-21 | 南京农业大学 | 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用 |
| US20120058537A1 (en) | 2011-07-27 | 2012-03-08 | Fereidoun Mahboudi | Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1 |
| WO2013024074A1 (en) | 2011-08-12 | 2013-02-21 | Thrombogenics N.V. | Plasminogen and plasmin variants |
| CN102532326B (zh) | 2011-11-18 | 2017-06-09 | 南京大学 | 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用 |
| CN103656630B (zh) | 2012-09-11 | 2015-07-08 | 江苏仁寿药业有限公司 | 一种提纯动物药材中纤溶酶并制备成中药组合物的方法 |
| US9718760B2 (en) | 2012-10-31 | 2017-08-01 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof |
| US9134326B2 (en) | 2013-03-14 | 2015-09-15 | Battelle Memorial Institute | Biomarkers for liver fibrosis |
| TWI689490B (zh) | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療纖維化之經取代之芳族化合物及相關方法 |
| EP2976321A1 (en) * | 2013-03-20 | 2016-01-27 | Elevance Renewable Sciences, Inc. | Acid catalyzed oligomerization of alkyl esters and carboxylic acids |
| CN104274449A (zh) | 2013-07-11 | 2015-01-14 | 无锡信达医疗器械有限公司 | 治疗肥胖症的药物组合物 |
| US9845363B2 (en) | 2013-08-13 | 2017-12-19 | Sanofi | Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof |
| TW201722994A (zh) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| US20160199466A1 (en) | 2013-08-20 | 2016-07-14 | Trustees Of Dartmouth College | Methods For Treating Tissue Fibrosis |
| EP3233111B1 (en) | 2014-12-19 | 2024-08-07 | Kedrion Biopharma Inc. | Pharmaceutical composition comprising plasminogen and uses thereof |
| TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| DK3391902T5 (da) | 2015-12-18 | 2024-09-23 | Talengen Int Ltd | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
| CN108778307A (zh) | 2015-12-18 | 2018-11-09 | 泰伦基国际有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| EP3391901B1 (en) | 2015-12-18 | 2023-07-05 | Talengen International Limited | Plasminogen for use in treating liver tissue damage |
| US11400142B2 (en) | 2015-12-18 | 2022-08-02 | Talengen International Limited | Treatment of diabetic nerve injury comprising administering plasminogen |
| TWI653982B (zh) | 2015-12-18 | 2019-03-21 | 大陸商深圳瑞健生命科學研究院有限公司 | Method for preventing or treating acute and chronic thrombosis |
| JP2019500426A (ja) | 2015-12-18 | 2019-01-10 | タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 糖尿病網膜症を予防または治療するための方法 |
| CN110366425A (zh) * | 2016-12-15 | 2019-10-22 | 泰伦基国际有限公司 | 一种预防动脉粥样硬化及其并发症的方法 |
| EP3556385A4 (en) | 2016-12-15 | 2020-12-30 | Talengen International Limited | PROCESS FOR ALLEGING HEART DISEASE |
| WO2018108161A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| TWI868051B (zh) | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
-
2017
- 2017-06-19 CN CN201780078105.0A patent/CN110366425A/zh active Pending
- 2017-06-19 CN CN201780078118.8A patent/CN110167583A/zh active Pending
- 2017-06-19 CA CA3047168A patent/CA3047168A1/en active Pending
- 2017-06-19 TW TW106120492A patent/TWI746580B/zh active
- 2017-06-19 EP EP17881831.6A patent/EP3556391A4/en active Pending
- 2017-06-19 TW TW106120464A patent/TWI684459B/zh active
- 2017-06-19 WO PCT/CN2017/089044 patent/WO2018107685A1/zh not_active Ceased
- 2017-06-19 EP EP17881180.8A patent/EP3556387A4/en active Pending
- 2017-06-19 WO PCT/CN2017/089052 patent/WO2018107692A1/zh not_active Ceased
- 2017-06-19 TW TW106120463A patent/TWI680764B/zh active
- 2017-06-19 CN CN201780078126.2A patent/CN110114082A/zh active Pending
- 2017-06-19 TW TW106120501A patent/TW201822812A/zh unknown
- 2017-06-19 JP JP2019532073A patent/JP7160351B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089046 patent/WO2018107687A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089049 patent/WO2018107690A1/zh not_active Ceased
- 2017-06-19 CA CA3047167A patent/CA3047167A1/en not_active Abandoned
- 2017-06-19 TW TW106120491A patent/TW201822805A/zh unknown
- 2017-06-19 US US16/469,618 patent/US11478535B2/en active Active
- 2017-06-19 US US16/469,599 patent/US11547746B2/en active Active
- 2017-06-19 CN CN201780078127.7A patent/CN110114083A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089051 patent/WO2018107691A1/zh not_active Ceased
- 2017-06-19 JP JP2019532071A patent/JP7161217B2/ja active Active
- 2017-06-19 TW TW106120499A patent/TW201822810A/zh unknown
- 2017-06-19 US US16/470,174 patent/US20190328850A1/en not_active Abandoned
- 2017-06-19 WO PCT/CN2017/089047 patent/WO2018107688A1/zh not_active Ceased
- 2017-06-19 TW TW110105040A patent/TW202123963A/zh unknown
- 2017-06-19 EP EP17882244.1A patent/EP3556393A4/en active Pending
- 2017-06-19 CA CA3047169A patent/CA3047169A1/en not_active Abandoned
- 2017-06-19 JP JP2019532070A patent/JP7158740B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089043 patent/WO2018107684A1/zh not_active Ceased
- 2017-06-19 TW TW106120498A patent/TW201822809A/zh unknown
- 2017-06-19 US US16/469,611 patent/US20190351033A1/en not_active Abandoned
- 2017-06-19 CA CA3046664A patent/CA3046664C/en active Active
- 2017-06-19 WO PCT/CN2017/089045 patent/WO2018107686A1/zh not_active Ceased
- 2017-06-19 TW TW106120465A patent/TWI750189B/zh active
- 2017-06-19 JP JP2019531975A patent/JP7214225B2/ja active Active
- 2017-06-19 EP EP17882245.8A patent/EP3556394A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502154A5 (enExample) | ||
| Begriche et al. | Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver | |
| JP2020510627A5 (enExample) | ||
| JP2020502156A5 (enExample) | ||
| Zheng et al. | Angiotensin-converting enzyme gene polymorphism and severe lung injury in patients with coronavirus disease 2019 | |
| JP2020511416A5 (enExample) | ||
| Chavez et al. | Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms | |
| JP2020502153A5 (enExample) | ||
| CN110366425A (zh) | 一种预防动脉粥样硬化及其并发症的方法 | |
| JP2020502155A5 (enExample) | ||
| Grace et al. | Proposed mechanism for increased COVID-19 mortality in patients with decompensated cirrhosis | |
| JP2012515165A5 (enExample) | ||
| Liu et al. | Polymer‐functionalized mitochondrial transplantation to plaque macrophages as a therapeutic strategy targeting atherosclerosis | |
| Chawla et al. | Permissive hypofiltration | |
| JP2020502134A5 (enExample) | ||
| Gilbert et al. | Caspase-(8/3) activation and organ inflammation in a rat model of resuscitated hemorrhagic shock: A role for uric acid | |
| Kaysen | Metabolic syndrome and renal failure: similarities and differences | |
| Neureiter | New in Hedgehog signaling: A possible role in aging, and chronic degenerative and inflammatory diseases?(Comment on DOI. | |
| Sargsyan et al. | HGFAC is a ChREBP regulated hepatokine that enhances glucose and lipid homeostasis | |
| Jefferies et al. | Heart failure treatment in the intensive care unit in children | |
| JP2009067793A (ja) | 抗アテローム血栓剤およびアンギオテンシン変換酵素阻害剤の組み合わせ | |
| ORLIEN et al. | Treatment of chronic hepatitis B in sub-saharan Africa: 5-year results of a pilot program in Ethiopia | |
| Zheng et al. | Is it necessary to stent renal artery stenosis patients before cardiopulmonary bypass procedures? | |
| Díez | Angiotensin II and the hypertensive heart: a role for the AT: 2: receptor? | |
| Paraíso et al. | Portosystemic encephalopathy in a patient treated with peritoneal dialysis |